Similar response rates and superior early progression‐free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma
Open Access
- 2 December 2005
- Vol. 106 (2), 353-360
- https://doi.org/10.1002/cncr.21587
Abstract
BACKGROUND The objective of this study was to compare the response rates, ability to mobilize autologous hematopoietic (peripheral blood) stem cells (PBSCs), and progression‐free survival (PFS) after second‐line chemotherapy with either gemcitabine, dexamethasone, and cisplatin (GDP) or carmustine, etoposide, cytarabine, and melphalan (mini‐BEAM) followed by high‐dose therapy and hematopoietic stem cell transplantation (ASCT) for patients with recurrent or refractory Hodgkin lymphoma. METHODS The outcomes of 68 consecutive patients who were referred for salvage therapy (34 patients received mini‐BEAM, and 34 patients received GDP) were compared retrospectively. Patients received mini‐BEAM as inpatient treatment every 3–4 weeks, whereas GDP was administered on an outpatient basis every 3 weeks. Responding patients proceeded to stem cell mobilization, followed by high dose etoposide and melphalan, and ASCT. Patients who had disease bulk at recurrence that measured > 5 cm received involved‐field radiation post‐ASCT. RESULTS The response rate to GDP prior to ASCT (complete responses, unconfirmed complete responses, and partial responses) was 62% (95% confidence interval [95% CI], 45–78%) compared with 68% (95% CI, 52–83%) for mini‐BEAM (P = 0.61). After mobilizing chemotherapy, the proportion of patients for whom the target PBSC number of ≥ 5 × 106 CD34‐positive cells/kg was obtained was 97% after GDP and 57% after MB (P = 0.0003). More patients completed collection with a single apheresis procedure after GDP than after mini‐BEAM (73% vs. 36%; P = 0.004), and fewer patients in the GDP group required bone marrow harvesting to proceed to ASCT. After a median follow‐up of 1.8 years after ASCT, PFS was significantly better for patients who received GDP compared with patients who received mini‐BEAM (74% vs. 35% at 1.5 yrs, respectively; P = 0.005). Overall survival at 1.5 years was 91% after GDP and 82% after mini‐BEAM (P = 0.23). CONCLUSIONS Although this was a retrospective analysis, response to GDP and early PFS after ASCT compared favorably with mini‐BEAM salvage chemotherapy. Based on these data, the authors believe that a Phase III trial comparing GDP with mini‐BEAM or other platinum‐containing regimens is warranted. Cancer 2006. © 2005 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupAnnals of Oncology, 2003
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002
- Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 TrialJournal of Clinical Oncology, 2002
- New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study GroupJournal of Clinical Oncology, 2002
- Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin’s diseaseEuropean Journal of Cancer, 1999
- Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cellsBone Marrow Transplantation, 1998
- VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s diseaseBone Marrow Transplantation, 1998
- Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1997
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993